Current Studies

Here is a list of some of our current studies. For additional studies, please visit RecruitMe.

 

  • Principal Investigator

    Helen Blair Simpson, MD, PhD
    If you answered "yes" to all four questions, you may be eligible for a study involving a researchmedication for OCD. Eligible participants will be asked questions about their symptoms and completea medical evaluation. You will receive a medication, and be monitored by medical professionals. Youwill also be asked to complete questionnaires. The purpose of this study is to assess to evaluate amedication for the treatment of OCD.
  • Principal Investigator

    J. John Mann, MD
    Depression affects 15 million Americans each year. Depression and suicidal behavior are transmitted in families due to a combination of genes and environment. Depressive illness and the risk of suicidal behavior are associated with altered brain function that we can detect with brain imaging. Therefore, this study aims to examine brain function in adults who have a relative who has suffered from depression and made a suicide attempt. The goal of the study is to detect which adult children are at risk of developing depression and who is not going to develop depression.
  • Principal Investigator

    Frances R. Levin, MD
    The study is a two group outpatient study, one group receiving medications (Adderall-XR and topiramate) and one group receiving a placebo (inactive sugar pill). The study is looking at the safety and effectiveness of Adderall-XR (MAS-ER) and topiramate in the treatment of cocaine dependence. It is a 14-week trial that requires patients to attend visits 3 times per week.
  • Principal Investigator

    Jonathan E. Posner, MD
    In this study, we are trying to learn more about how stimulant medication produces an improvement in emotional lability (frequent mood changes and excessive emotional reactions) in patients with ADHD. Although ADHD is primarily associated with inattention, hyperactivity, and impulsivity, emotional lability plays a crucial role in the disorder. The study involves psychiatric evaluations, magnetic resonance imaging (MRI) scans, and treatment with either a medication called Vyvanse (lisdexamfetamine dimesylate) or a placebo (a pill with no active drug ingredient).
  • The Neurocognition of Language Laboratory is seeking children from 6 12 years of age to participate in a brain study of visual-sensory processing. We will use a technique called electroencephalography (EEG) to measure the brains electrical activity by placing small electrodes that rest on the scalp. EEG is pain-free, safe, and non- invasive. We are looking for children with autism spectrum disorder (ASD) who do not take psychiatric medications and neurotypical children without psychiatric diagnoses.

  • Principal Investigator

    Franklin R. Schneier, MD
    We are currently enrolling individuals with social anxiety disorder to participate inthis study. The purpose of this study is to assess whether a brief computer-basedresearch treatment helps improve social anxiety symptoms. For eligibleparticipants, this study will involve a brief, novel research treatment for socialanxiety, delivered in 8 or 12 sessions over the course of 4 or 8 weeks.Participants will receive payment for completing study assessments. The studywill also assess the effect of research treatments on brain activity using a scancalled magnetic resonance imaging (MRI).
  • Principal Investigator

    Helen Blair Simpson, MD, PhD
    The purpose of this pilot research study is to test the effects of a medication called nabilone (Cesamet) in adults with obsessive-compulsive disorder (OCD). Participants will receive either nabilone on its own, or nabilone in combination with a form of cognitive-behavioral therapy (CBT) called exposure and response prevention (EX/RP). Nabilone is a synthetic cannabinoid and acts on the brain's "endocannabinoid system," which has been hypothesized to play a role in OCD. Nabilone is approved by the FDA for the treatment of chemotherapy-induced nausea and vomiting.
  • Principal Investigator

    Helen Blair Simpson, MD, PhD
    This study is investigating how the brains of people with OCD may change with treatment. The study uses Magnetic Resonance Imaging (MRI) to scan the brain, and the treatment used is a form of Cognitive-Behavioral therapy consisting of Exposure and Ritual Prevention (EX/RP). Participants will undergo a scan, which lasts for approximately 2 hours and takes images (pictures) of your brain. Participants will then be offered 17 sessions of EX/RP treatment over 9-10 weeks, and will undergo a second scan at the end of this treatment.
  • Principal Investigator

    Patrick J. Brown, PhD
    The goal of this open-administration treatment study of escitalopram (or duloxetine) is to evaluate the effect of antidepressant medication on treating the syndrome of frailty in older adults with depressive symptoms. Patients with significant depressive symptoms and 1 or more symptoms of the frailty syndrome (exhaustion, decreased energy, weight loss, decreased grip strength, and slow/unsteady gait) will be evaluated and treated with approved antidepressant medication for 8 weeks to test whether antidepressant medication improves both the syndrome of frailty and depressive symptoms.
  • Principal Investigator

    Helen Blair Simpson, MD, PhD
    The purpose of this pilot research study is to test whether certain components of the marijuana plant, known as "cannabinoids", may help to reduce symptoms in patients with OCD. Specifically, patients enrolled in the study will smoke marijuana containing different concentrations of 2 different cannabinoids, THC and CBD. Both of these agents act on the brain's "endocannabinoid system," which has been hypothesized to play a role in OCD. Neither compound is currently FDA-approved for treating OCD.
  • Principal Investigator

    J. John Mann, MD
    This research study uses brain imaging to explore the biological causes of depression and of suicidal behavior. Suicidal behavior and major depression are transmitted in families. Some family members are at risk and others are resilient. The investigators hope to develop a better understanding of how those family members at risk differ from those who are resilient, and hope to figure out how to make those at risk more like those who are resilient. This is real prevention because we want to prevent people from ever becoming depressed in the first place.
  • Principal Investigator

    J. John Mann, MD
    This research study uses brain imaging to explore the biological causes of depression and suicidal behavior. The investigators hope to develop a better understanding of how people who attempt suicide differ from those who don't in order to improve prevention. Participation includes brain imaging scans (MRI and PET), neuropsychological tasks and clinical assessment. Eligible individuals will be compensated up to $475.
  • Principal Investigator

    J. John Mann, MD
    This research study uses brain imaging to explore the biological causes of major depression and why some people feel suicidal or may act on such thoughts. The investigators hope to develop a better understanding of how people who feel depressed and suicidal cope with their feelings to improve treatment and prevention. Individuals may qualify if they have depression with or without suicidal thoughts or any history of suicide attempts. Participation involves a detailed diagnostic set of interviews, brain imaging scans (MRI and PET) and neuropsychological tasks.
  • Principal Investigator

    Bret R. Rutherford, MD
    In this research study, you may receive treatment for depression with an FDA approved medication called escitalopram (Lexapro) or placebo. Escitalopram is a Selective Serotonin Reuptake Inhibitor (SSRI) medication that appears to help with symptoms of depression by increasing the availability of specific chemicals in the brain. A placebo is a sugar pill. The purpose of this study is to determine how treatment response may change depending on how studies are designed.
  • Principal Investigator

    Frances R. Levin, MD
    The study is an outpatient treatment study of the safety and benefit of extended-release mixed amphetamine salt (Adderall-XR) in the treatment of individuals with cannabis use disorder and Attention Deficit/Hyperactivity Disorder (ADHD). The study is a 13-week trial and requires participants to come twice per week. The primary objective of the study is to determine the safety and effectiveness of Adderall-XR in decreasing marijuana use and in promoting a decrease in ADHD symptoms.
  • Principal Investigator

    Martin Picard, PhD
    This study examines normal individual differences in the ways that the body and the brain respond to emotions, and the role of mitochondria in the mind-body connection. Mitochondria are small parts of each cell that make energy to keep us alive. Participants will be asked to come for a single two full-day visit, including two nights at a hotel next to the research center (Columbia University Medical Center). The study visit will include a blood draw, a medical exam, a cognitive testing session, questionnaires, an MRI scan, and at-home collection of saliva and stool samples the following week.
  • Principal Investigator

    Bret R. Rutherford, MD
    Cognitive decline is highly prevalent in individuals with hearing impairment. Hearing deficits have been implicated with a decreased performance on various cognitive tests, but it is unclear whether this is associated with severe cognitive decline or dementia. In this study, we hope to better characterize theassociation between hearing impairment, depression, and major cognitive decline or dementia. We will also be looking at how hearing loss may affect an individuals clinical response to an antidepressant.
  • Principal Investigator

    Jeremy Veenstra-Vanderweele, MD
    The Translational Medicine Program at the Center for Autism and the Developing Brain is recruiting individuals with autism from 5 17 years of age with an IQ over 70 to participate in our study called aV1ation. The purpose of this study is to test an investigational medicine that blocks a hormone receptor in the brain linked to the control of socialization, stress, anxiety and aggression. We want to see if this medicine is effective as a treatment to help improve social functioning in children with ASD.
  • Principal Investigator

    Mate I. Milak, MD
    Overview of the Research Study: This study uses brain-scanning technology (MRI) to help understand actions of an experimental antidepressant called ketamine, which is used widely in higher doses for anesthesia. In this study, we seek to determine whether HNKs (which are made from ketamine in the body) are responsible for ketamine's antidepressant effect. If there is any benefit, it is expected to appear within 24 hours.
  • Principal Investigator

    Helen Blair Simpson, MD, PhD
    The Center for OCD and Related Disorders and the Institute of Genomic Medicine is conducting a study to look for genetic causes of OCD. Our goal is to look at the genes of individuals with OCD to see if we can identify what may have put those individuals at risk for OCD. Participants will receive a clinical evaluation at no cost, a blood draw (up to 2 tablespoons) and compensation for their time. Significant findings from these genetic tests will be reported back to participants (if they chose to be notified of results).
  • Principal Investigator

    Joan Prudic, MD
    We are performing functional MRI (fMRI) scans before starting and after completing an acute course of electroconvulsive therapy (ECT) treatment. These scans are being performed to identify brain changes that occur after an acute course of ECT for participants with treatment-resistant depression. We also intend to perform two follow-up fMRI scans at two-months and six-months post-treatment to continue monitoring brain changes, as well as to track participants' progress as they become further removed from their course of ECT anti-depressant treatment.
  • Principal Investigator

    Bret R. Rutherford, MD
    In this research study, you will be fitted with hearing aids that may be fully tuned to improve your hearing (full dose) or may be only partially tuned and not likely to substantially improve your hearing (low dose). You will receive a free hearing aid that will be at full dose at the end of the 12 week study. You may also choose to receive treatment for depression with an FDA approved medication called escitalopram (Lexapro) or duloxetine (Cymbalta).
  • Principal Investigator

    Eleanor McGlinchey, PhD
    We are conducting research to compare different ways of improving sleep and mood in teens. Treatment involves Behavioral Sleep Therapy and Interpersonal Psychotherapy for Adolescents targeting: depression trouble falling and staying asleep not feeling rested on waking feeling sleepy during the dayStudy Procedures: ~ A free, thorough diagnostic evaluation ~ A full course of therapy (8-20 sessions) at no cost ~ Saliva collection and sleep monitoring before and after treatment ~ Study evaluations and treatment will be provided at no cost to you.